Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/198429
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma |
Autor: | Sheffield, Nathan C.; Pierron, Gaelle; Klughammer, Johanna; Datlinger, Paul; Schönegger, Andreas; Schuster, Michael; Hadler, Johanna; Surdez, Didier; Guillemot, Delphine; Lapouble, Eve; Freneaux, Paul; Champigneulle, Jacqueline; Bouvier, Raymonde; Walder, Diana; Ambros, Ingeborg M.; Hutter, Caroline; Sorz, Eva; Amaral, Ana Teresa CSIC; Álava, Enrique de CSIC ORCID; Schallmoser, Katharina; Strunk, Dirk; Rinner, Beate; Liegl-Atzwanger, Bernadette; Huppertz, Berthold; Leithner, Andreas; Pinieux, Gonzague de; Terrier, Philippe; Laurence, Valérie; Michon, Jean; Ladenstein, Ruth; Holter, Wolfgang; Windhager, Reinhard; Dirksen, Uta; Ambros, Peter F.; Delattre, Olivier; Kovar, Heinrich; Bock, Christoph; Tomazou, Eleni M. | Fecha de publicación: | 30-ene-2017 | Editor: | Springer Nature | Citación: | Nature medicine 23: 386-395 (2017) | Resumen: | Developmental tumors in children and young adults carry few genetic alterations, yet they have diverse clinical presentation. Focusing on Ewing sarcoma, we sought to establish the prevalence and characteristics of epigenetic heterogeneity in genetically homogeneous cancers. We performed genome-scale DNA methylation sequencing for a large cohort of Ewing sarcoma tumors and analyzed epigenetic heterogeneity on three levels: between cancers, between tumors, and within tumors. We observed consistent DNA hypomethylation at enhancers regulated by the disease-defining EWS-FLI1 fusion protein, thus establishing epigenomic enhancer reprogramming as a ubiquitous and characteristic feature of Ewing sarcoma. DNA methylation differences between tumors identified a continuous disease spectrum underlying Ewing sarcoma, which reflected the strength of an EWS-FLI1 regulatory signature and a continuum between mesenchymal and stem cell signatures. There was substantial epigenetic heterogeneity within tumors, particularly in patients with metastatic disease. In summary, our study provides a comprehensive assessment of epigenetic heterogeneity in Ewing sarcoma and thereby highlights the importance of considering nongenetic aspects of tumor heterogeneity in the context of cancer biology and personalized medicine. | Versión del editor: | http://dx.doi.org/10.1038/nm.4273 | URI: | http://hdl.handle.net/10261/198429 | DOI: | 10.1038/nm.4273 | Identificadores: | doi: 10.1038/nm.4273 e-issn: 1546-170X issn: 1078-8956 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
108
checked on 26-mar-2024
SCOPUSTM
Citations
160
checked on 06-may-2024
WEB OF SCIENCETM
Citations
142
checked on 29-feb-2024
Page view(s)
204
checked on 10-may-2024
Download(s)
21
checked on 10-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.